{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:29:50Z","timestamp":1788492590784,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.steroids.2024.109475","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T06:06:35Z","timestamp":1721973995000},"page":"109475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Steroidal 21-imidazolium salt derivatives: Synthesis and anticancer activity"],"prefix":"10.1016","volume":"210","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8733-3040","authenticated-orcid":false,"given":"Natalia S.","family":"Sucman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4283-2510","authenticated-orcid":false,"given":"Dmitri","family":"Ya. Bilan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-5390","authenticated-orcid":false,"given":"Sergiu V.","family":"Cojocari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4882-3140","authenticated-orcid":false,"given":"Vsevolod S.","family":"Pogrebnoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0731-3424","authenticated-orcid":false,"given":"Eugenia P.","family":"St\u00eengaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-9860","authenticated-orcid":false,"given":"Vladimir A.","family":"Khripach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-2794","authenticated-orcid":false,"given":"Vladimir N.","family":"Zhabinskii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-0437","authenticated-orcid":false,"given":"Tatsiana V.","family":"Tsybruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina P.","family":"Grabovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7896-4430","authenticated-orcid":false,"given":"Olesya V.","family":"Panibrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leentje","family":"Persoons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Schols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathy","family":"Froeyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1222-4373","authenticated-orcid":false,"given":"Sergiu","family":"Shova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"De Jonghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3094-1990","authenticated-orcid":false,"given":"Fliur Z.","family":"Macaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.steroids.2024.109475_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-121211-091605","article-title":"Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer","volume":"64","author":"Ferraldeschi","year":"2013","journal-title":"Annu. Rev. Med."},{"issue":"13","key":"10.1016\/j.steroids.2024.109475_b0010","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1021\/jm00013a022","article-title":"Novel steroidal inhibitors of human cytochrome P45017\u03b1 (17\u03b1-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer","volume":"38","author":"Potter","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109475_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsbmb.2014.01.013","article-title":"A-Ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone","volume":"143","author":"Garrido","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109475_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2023.106362","article-title":"Novel D-modified heterocyclic androstane derivatives as potential anticancer agents: Synthesis, characterization, in vitro and in silico studies","volume":"233","author":"\u0160esti\u0107","year":"2023","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"11","key":"10.1016\/j.steroids.2024.109475_b0025","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.4155\/fmc-2024-0039","article-title":"Synthesis, in vitro and in silico anticancer evaluation of novel pyridin-2-yl estra-1,3,5(10)-triene derivatives","volume":"16","author":"Stevanovi\u0107","year":"2024","journal-title":"Future Med. Chem."},{"issue":"22","key":"10.1016\/j.steroids.2024.109475_b0030","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1016\/j.bmc.2015.10.015","article-title":"Androstane derivatives induce apoptotic death in MDA-MB-231 breast cancer cells","volume":"23","author":"Jakimov","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.steroids.2024.109475_b0035","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.bmc.2015.02.001","article-title":"Synthesis, structural analysis and antitumor activity of novel 17\u03b1-picolyl and 17(E)-picolinylidene A-modified androstane derivatives","volume":"23","author":"Ajdukovi\u0107","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"23","key":"10.1016\/j.steroids.2024.109475_b0040","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1016\/j.bmc.2013.09.063","article-title":"17(E)-Picolinylidene androstane derivatives as potential inhibitors of prostate cancer cell growth: antiproliferative activity and molecular docking studies","volume":"21","author":"Ajdukovic","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109475_b0045","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ejmech.2012.06.030","article-title":"Synthesis and cytotoxic activity of some 17-picolyl and 17-picolinylidene androstane derivatives","volume":"54","author":"Djurendi\u0107","year":"2012","journal-title":"Eur. J. Med. Chem."},{"issue":"20","key":"10.1016\/j.steroids.2024.109475_b0050","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1021\/jm970337k","article-title":"17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P45017\u03b1)","volume":"40","author":"Ling","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109475_b0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.steroids.2018.08.004","article-title":"New azole derivatives of [17(20)E]-21-norpregnene: synthesis and inhibition of prostate carcinoma cell growth","volume":"147","author":"Dalidovich","year":"2019","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2024.109475_b0060","doi-asserted-by":"crossref","first-page":"13534","DOI":"10.3390\/ijms232113534","article-title":"Synthesis and biological evaluation of new isoxazolyl steroids as anti-prostate cancer agents","volume":"23","author":"Rudovich","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.steroids.2024.109475_b0065","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/jm970568r","article-title":"Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17\u03b1-hydroxylase-C17,20-lyase (P45017\u03b1): potential agents for the treatment of prostate cancer","volume":"41","author":"Njar","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109475_b0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.steroids.2014.06.014","article-title":"Novel oxazolinyl derivatives of pregna-5,17(20)-diene as 17\u03b1-hydroxylase\/17,20-lyase (CYP17A1) inhibitors","volume":"88","author":"Kuzikov","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2024.109475_b0075","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.steroids.2016.06.002","article-title":"Oxazolinyl derivatives of [17(20)E]-21-norpregnene differing in the structure of A and B rings. Facile synthesis and inhibition of CYP17A1 catalytic activity","volume":"115","author":"Kostin","year":"2016","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2024.109475_b0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.steroids.2017.11.009","article-title":"Comparison of [17(20)E]-21-norpregnene oxazolinyl and benzoxazolyl derivatives as inhibitors of CYP17A1 activity and prostate carcinoma cells growth","volume":"129","author":"Zolottsev","year":"2018","journal-title":"Steroids"},{"issue":"45","key":"10.1016\/j.steroids.2024.109475_b0085","doi-asserted-by":"crossref","first-page":"e202203393","DOI":"10.1002\/slct.202203393","article-title":"Design and synthesis of new agents for prostate cancer treatment inspired by steroidal CYP17 A1 inhibitors","volume":"7","author":"Zolottsev","year":"2022","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.steroids.2024.109475_b0090","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2147\/DDDT.S93941","article-title":"Galeterone for the treatment of advanced prostate cancer: the evidence to date","volume":"10","author":"Bastos","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"issue":"8","key":"10.1016\/j.steroids.2024.109475_b0095","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1535-7163.MCT-08-0230","article-title":"Androgen receptor inactivation contributes to antitumor efficacy of 17\u03b1-hydroxylase\/17,20-lyase inhibitor 3\u03b2-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer","volume":"7","author":"Vasaitis","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.steroids.2024.109475_b0100","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.2147\/DDDT.S307113","article-title":"Imidazole as a promising medicinal scaffold: Current status and future direction","volume":"15","author":"Alghamdi","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.steroids.2024.109475_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2019.03.003","article-title":"Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR\/CYP17 for the treatment of prostate cancer","volume":"150","author":"Hou","year":"2019","journal-title":"Steroids"},{"issue":"8","key":"10.1016\/j.steroids.2024.109475_b0110","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1021\/jm040202w","article-title":"Novel C-17-heteroaryl steroidal CYP17 inhibitors\/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model","volume":"48","author":"Handratta","year":"2005","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.steroids.2024.109475_b0115","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1021\/jm400048v","article-title":"Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer","volume":"56","author":"Purushottamachar","year":"2013","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.steroids.2024.109475_b0120","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1021\/jm501239f","article-title":"Discovery and development of galeterone (TOK-001 or VN\/124-1) for the treatment of all stages of prostate cancer","volume":"58","author":"Njar","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109475_b0125","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ejmech.2019.06.040","article-title":"Synthesis of novel galeterone derivatives and evaluation of their in vitro activity against prostate cancer cell lines","volume":"179","author":"Jorda","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109475_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.steroids.2019.108534","article-title":"New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone","volume":"153","author":"Latysheva","year":"2020","journal-title":"Steroids"},{"issue":"6","key":"10.1016\/j.steroids.2024.109475_b0135","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.eururo.2019.08.034","article-title":"Androgen receptor modulation optimized for response-splice variant: a phase 3, randomized trial of galeterone versus enzalutamide in androgen receptor splice variant-7-expressing metastatic castration-resistant prostate cancer","volume":"76","author":"Taplin","year":"2019","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.steroids.2024.109475_b0140","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.bmc.2017.01.018","article-title":"Synthesis of new derivatives of 21-imidazolyl-16-dehydropregnenolone as inhibitors of 5\u03b1-reductase 2 and with cytotoxic activity in cancer cells","volume":"25","author":"Silva-Ortiz","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109475_b0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jsbmb.2016.02.013","article-title":"Synthesis and biological activity of two pregnane derivatives with a triazole or imidazole ring at C-21","volume":"159","author":"Silva-Ortiz","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"22","key":"10.1016\/j.steroids.2024.109475_b0150","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.3390\/ijms222212180","article-title":"Steroid-functionalized imidazolium salts with an extended spectrum of antifungal and antibacterial activity","volume":"22","author":"Malinowska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.steroids.2024.109475_b0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jsbmb.2019.02.006","article-title":"Synthesis and antimicrobial properties of steroid-based imidazolium salts","volume":"189","author":"Hryniewicka","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2024.109475_b0160","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejmech.2019.02.025","article-title":"Synthesis and antitumor activity of novel steroidal imidazolium salt derivatives","volume":"168","author":"Deng","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.steroids.2024.109475_b0165","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.steroids.2018.01.004","article-title":"Synthesis and cytotoxic effect of pregnenolone derivatives with one or two \u03b1, \u03b2-unsaturated carbonyls and an ester moiety at C-21 or C-3","volume":"131","author":"Chavez-Riveros","year":"2018","journal-title":"Steroids"},{"issue":"5","key":"10.1016\/j.steroids.2024.109475_b0170","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0039-128X(84)90120-X","article-title":"An efficient synthesis of 3\u03b1-hydroxy-5\u03b1-pregna-9(11),16-dien-20-one","volume":"43","author":"Kim","year":"1984","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2024.109475_b0175","series-title":"CrysAlis Pro Software System","author":"Rigaku Oxford Diffraction","year":"2015"},{"issue":"1","key":"10.1016\/j.steroids.2024.109475_b0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053273314026370","article-title":"SHELXT \u2013 integrated space-group and crystal-structure determination","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr. Sect. A"},{"issue":"Pt 1","key":"10.1016\/j.steroids.2024.109475_b0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053229614024218","article-title":"Crystal structure refinement with SHELXL","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr. C Struct. Chem."},{"issue":"2","key":"10.1016\/j.steroids.2024.109475_b0190","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1107\/S0021889808042726","article-title":"OLEX2: a complete structure solution, refinement and analysis program","volume":"42","author":"Dolomanov","year":"2009","journal-title":"J. Appl. Crystallogr."},{"issue":"7","key":"10.1016\/j.steroids.2024.109475_b0195","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1134\/S0006297908070092","article-title":"Engineering, expression, and purification of \u201csoluble\u201d human cytochrome P45017\u03b1 and its functional characterization","volume":"73","author":"Pechurskaya","year":"2008","journal-title":"Biochemistry (mosc)"},{"issue":"11","key":"10.1016\/j.steroids.2024.109475_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11112873","article-title":"Molecular cloning, heterologous expression, purification, and evaluation of protein-ligand interactions of CYP51 of Candida krusei azole-resistant fungal strain","volume":"11","author":"Tsybruk","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.steroids.2024.109475_b0205","unstructured":"T.L. Riss, R.A. Moravec, A.L. Niles, S. Duellman, H.A. Benink, T.J. Worzella, L. Minor, Cell Viability Assays, in: S. Markossian, A. Grossman, K. Brimacombe, M. Arkin, D. Auld, C. Austin, J. Baell, T.D.Y. Chung, N.P. Coussens, J.L. Dahlin, V. Devanarayan, T.L. Foley, M. Glicksman, K. Gorshkov, J.V. Haas, M.D. Hall, S. Hoare, J. Inglese, P.W. Iversen, S.C. Kales, M. Lal-Nag, Z. Li, J. McGee, O. McManus, T. Riss, P. Saradjian, G.S. Sittampalam, M. Tarselli, O.J. Trask, Jr., Y. Wang, J.R. Weidner, M.J. Wildey, K. Wilson, M. Xia, X. Xu (Eds.), Assay Guidance Manual, Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD), 2004."},{"issue":"7383","key":"10.1016\/j.steroids.2024.109475_b0210","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature10743","article-title":"Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001","volume":"482","author":"DeVore","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.steroids.2024.109475_b0215","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J Chem Inf Model"},{"issue":"11","key":"10.1016\/j.steroids.2024.109475_b0220","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/jcc.540141112","article-title":"General atomic and molecular electronic structure system","volume":"14","author":"Schmidt","year":"1993","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.steroids.2024.109475_b0225","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mce.2016.08.035","article-title":"Structural insights into the function of steroidogenic cytochrome P450 17A1","volume":"441","author":"Yadav","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2024.109475_b0230","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1039\/B205022F","article-title":"Facile C21 functionalization through a novel functional group transfer reaction in 16\u03b1,17\u03b1-epoxy-3\u03b2-hydroxypregn-5-en-20-one and its applications","volume":"18","author":"Girdhar","year":"2002","journal-title":"J. Chem. Soc.-Chem. Commun."},{"issue":"31","key":"10.1016\/j.steroids.2024.109475_b0235","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1016\/j.tet.2009.05.043","article-title":"Bismuth(III) triflate-catalyzed rearrangement of 16\u03b1,17\u03b1-epoxy-20-oxosteroids. Synthesis and structural elucidation of new 16\u03b1-substituted 17\u03b1-alkyl-17\u03b2-methyl-\u039413-18-norsteroids","volume":"65","author":"Pinto","year":"2009","journal-title":"Tetrahedron"},{"key":"10.1016\/j.steroids.2024.109475_b0240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/DDDT.S15850","article-title":"Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer","volume":"6","author":"Rehman","year":"2012","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.steroids.2024.109475_b0245","doi-asserted-by":"crossref","unstructured":"L.R. Engelking, Textbook of Veterinary Physiological Chemistry, 3rd ed., Academic Press, Amsterdam, 2015. https:\/\/doi.org\/10.1016\/C2010-0-66047-0.","DOI":"10.1016\/C2010-0-66047-0"},{"issue":"3","key":"10.1016\/j.steroids.2024.109475_b0250","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/pros.23459","article-title":"Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models","volume":"78","author":"Fiandalo","year":"2018","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.steroids.2024.109475_b0255","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1074\/jbc.M111.261933","article-title":"Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells","volume":"287","author":"Soifer","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.steroids.2024.109475_b0260","first-page":"139","article-title":"Anti-androgen abiraterone acetate improves the therapeutic efficacy of statins on castration-resistant prostate cancer cells","volume":"3","author":"Miller","year":"2017","journal-title":"J. Oncol. Res. Ther."},{"issue":"17","key":"10.1016\/j.steroids.2024.109475_b0265","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1021\/jm950749y","article-title":"3- and 4-Pyridylalkyl adamantanecarboxylates: inhibitors of human cytochrome P45017\u03b1(17\u03b1-hydroxylase\/C17,20-lyase). Potential nonsteroidal agents for the treatment of prostatic cancer","volume":"39","author":"Chan","year":"1996","journal-title":"J. Med. Chem."}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X24001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X24001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T11:39:33Z","timestamp":1728473973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X24001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":53,"alternative-id":["S0039128X24001132"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2024.109475","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Steroidal 21-imidazolium salt derivatives: Synthesis and anticancer activity","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2024.109475","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109475"}}